ResMed (RMD) reported strong first quarter earnings and reaffirmed its revenue outlook for fiscal 2027, while also declaring a quarterly dividend of $0.66 per share payable on December 17, 2026.
ResMed’s latest earnings and dividend news landed after a mixed stretch for investors, with the share price slipping 1.7% over the last day but gaining 6.9% over 90 days. The 1-year total shareholder return is down 5.5% and the 3-year total shareholder return is up 68.2%, suggesting long term momentum remains stronger than recent performance implies.
Spot opportunities beyond ResMed by scanning a curated set of resilient healthcare and quality-focused names in our 31 resilient stocks with low risk scores.ResMed has alternated between short term weakness and longer term strength, even as earnings and guidance have remained stable. Does that suggest a reasonable entry point now, or a case for patience and waiting for a lower price first?
Most Popular Narrative: 11% Undervalued
On the latest numbers, the most followed narrative pegs ResMed’s fair value at $265.11 compared with a last close of $235.30. This puts the focus firmly on whether that gap reflects opportunity or just optimistic modeling.
Supply chain productivity initiatives that have already widened gross margin by roughly 500 to 600 basis points in three years, combined with modest price increases and guidance for low double digit basis point margin improvement each year through 2030, point to an ongoing structural lift to gross margin and free cash flow.
See why 79 investors see ResMed as 11% undervalued.
Result: Fair Value of $265.11 (UNDERVALUED)
Still, the Astral ventilator corrective action and rising component and freight costs could pressure margins and quickly challenge the current narrative around ResMed’s undervaluation.
Find out about the key risks to this ResMed narrative.
Next Steps
Whether you are feeling cautious after all of this, or starting to lean optimistic on ResMed again, it can be useful to test the numbers yourself and see what holds up. To understand why some investors are focusing on its positives, take a closer look at the 4 key rewards.
Looking for more investment ideas beyond ResMed?
If ResMed has you thinking more broadly about your portfolio, use this moment to line up a few fresh watchlist candidates before the next move catches you off guard.
- Target resilience by scanning a list of solid balance sheet and fundamentals (25 results) that can help support earnings through tougher conditions.
- Hunt for mispriced opportunities and review a curated 38 high quality undervalued stocks that some investors use to source potential bargains.
- Strengthen your income stream by checking a focused 7 dividend fortresses that screens for higher yield with added scrutiny on sustainability.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com